Protalix Biotherapeutics Inc (NYSE:PLX) shares had already been on a solid 3% bump yesterday and in pre-market trading have gone on to race …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced its financial results for the full-year ended December 31, 2016, and provided a corporate update. “Recently, our Executive Vice …
Protalix BioTherapeutics Inc. (NYSE MKT:PLX) announced that pre-clinical data for AIR DNaseTM (PRX-110) for the treatment of Cystic Fibrosis will be presented at …
Protalix BioTherapeutics Inc. (NYSEMKT:PLX) reported financial results for the quarter ended March 31, 2015.
